Western blot analysis of Lane 1 : Negative control (vector only transfected HEK293T lysate), Lane 2: Over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY423056) with AKT1 polyclonal antibody (Cat # PAB28728) at 1:100-1:250 dilution.
Immunohistochemical staining of human gall bladder with AKT1 polyclonal antibody (Cat # PAB28728) shows strong nuclear positivity in glandular cells at 1:50-1:200 dilution.
Immunofluorescent staining of human cell line A-431 with AKT1 polyclonal antibody (Cat # PAB28728) at 1-4 ug/mL shows positivity in nucleus but not nucleoli and cytoskeleton (microtubules).
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq